KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway.
KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway; Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway.
Cytokine Growth Factor Rev. 2014 Jun;25(3):343-50. doi: 10.1016/j.cytogfr.2014.04.009. Epub 2014 May 9.
Multiple myeloma is characterized by slowly growing clones of malignant plasma cells in the bone marrow. The malignant state is frequently accompanied by osteolytic bone disease due to a disturbed balance between osteoblasts and osteoclasts. Bone morphogenetic proteins (BMPs) are present in the bone marrow and are important for several aspects of myeloma pathogenesis including growth and survival of tumor cells, bone homeostasis, and anemia. Among cancer cells, myeloma cells are particularly sensitive to growth inhibition and apoptosis induced by BMPs and therefore represent good models to study BMP receptor usage and signaling. Our review highlights and discusses the current knowledge on BMP signaling in myeloma.
多发性骨髓瘤的特征是骨髓中恶性浆细胞的克隆缓慢生长。恶性状态常伴有破骨细胞性骨病，这是由于成骨细胞和破骨细胞之间的平衡失调所致。骨形态发生蛋白（BMPs）存在于骨髓中，对于骨髓瘤发病机制的多个方面都很重要，包括肿瘤细胞的生长和存活、骨稳态和贫血。在癌细胞中，骨髓瘤细胞对 BMP 诱导的生长抑制和凋亡特别敏感，因此是研究 BMP 受体使用和信号转导的良好模型。我们的综述强调并讨论了目前关于骨髓瘤中 BMP 信号转导的知识。
